Antonio Tursi1, Walter Elisei2, Marcello Picchio3, Antonio Penna4, Piera Giuseppina Lecca5, Giacomo Forti6, GianMarco Giorgetti7, Roberto Faggiani8, Costantino Zampaletta8, Giorgio Pelecca8, Giovanni Brandimarte5. 1. Gastroenterology Service, ASL BAT, Andria, BT, Italy. Electronic address: antotursi@tiscali.it. 2. Division of Gastroenterology, ASL Roma H, Albano Laziale, Rome, Italy. 3. Division of Surgery, "P. Colombo" Hospital, Velletri, Rome, Italy. 4. Division of Gastroenterology, "San Paolo" Hospital, Bari, Italy. 5. Division of Gastroenterology, "Cristo Re" Hospital, Rome, Italy. 6. Digestive Endoscopy Unit, "Santa Maria Goretti" Hospital, Latina, Italy. 7. Digestive Endoscopy and Nutrition Unit, "S. Eugenio" Hospital, Rome, Italy. 8. Division of Gastroenterology, "Belcolle Hospital", Viterbo, Italy.
Abstract
BACKGROUND: Infliximab (IFX) and adalimumab (ADA) are the key treatments for Crohn's Disease (CD), unresponsive to standard treatments. Our aim was to compare the efficacy and safety of IFX and ADA in treating CD in clinical practice. METHODS: One hundred and twenty-six patients (61 M, 65 F, mean age 36.2 years, range 19-67 years), affected by CD, were treated with infliximab (IFX, 59 patients) or adalimumab (ADA, 66 patients). Clinical efficacy, mucosal healing (MH), histological healing (HH), and safety were assessed. MH was defined complicated if healing of ulcers occurred with deformation of bowel profile and/or complete colonoscopy was impossible because of scars. RESULTS: Patients were followed-up for 36 months. No difference was found between IFX and ADA in maintaining long-term clinical remission, MH and HH. Complicated MH was present in 17 (28.8%) patients in IFX group and in 7 (10.6%) patients in ADA group (p=0.012). In 9 (15.2%) patients in IFX group and 2 (3.0%) patients in ADA group colonoscopy was incomplete without cecal intubation or terminal ileum exploration (p=0.024). Side effects were similar in both groups. CONCLUSIONS: Both IFX and ADA seem to be effective and safe in long-term outpatient treatment of CD in clinical practice.
BACKGROUND:Infliximab (IFX) and adalimumab (ADA) are the key treatments for Crohn's Disease (CD), unresponsive to standard treatments. Our aim was to compare the efficacy and safety of IFX and ADA in treating CD in clinical practice. METHODS: One hundred and twenty-six patients (61 M, 65 F, mean age 36.2 years, range 19-67 years), affected by CD, were treated with infliximab (IFX, 59 patients) or adalimumab (ADA, 66 patients). Clinical efficacy, mucosal healing (MH), histological healing (HH), and safety were assessed. MH was defined complicated if healing of ulcers occurred with deformation of bowel profile and/or complete colonoscopy was impossible because of scars. RESULTS:Patients were followed-up for 36 months. No difference was found between IFX and ADA in maintaining long-term clinical remission, MH and HH. Complicated MH was present in 17 (28.8%) patients in IFX group and in 7 (10.6%) patients in ADA group (p=0.012). In 9 (15.2%) patients in IFX group and 2 (3.0%) patients in ADA group colonoscopy was incomplete without cecal intubation or terminal ileum exploration (p=0.024). Side effects were similar in both groups. CONCLUSIONS: Both IFX and ADA seem to be effective and safe in long-term outpatient treatment of CD in clinical practice.
Authors: Ashwin N Ananthakrishnan; Andrew Cagan; Tianxi Cai; Vivian S Gainer; Stanley Y Shaw; Guergana Savova; Susanne Churchill; Elizabeth W Karlson; Isaac Kohane; Katherine P Liao; Shawn N Murphy Journal: Inflamm Bowel Dis Date: 2016-04 Impact factor: 5.325